This registry will make it possible to describe real life management of patients with rare actionable fusions and to better understand these cancers. In addition of clinical data from the medical files, a quality of life questionnaire (QLQ-C30) will be complete at inclusion, at each new treatment and then every 6 months. The patients will be followed for a period of at least 2 years after the inclusion. This TRacKING registry is a European collaborative tool to improve the management of patients with actionable fusions, by sharing of data from rare tumor indications.
1. Administrative opening of the center 2. Routine identification of a patients harboring a rare actionable fusion 3. Patient's inclusion * Signature of written informed consent, * Declaration by the physician to the coordinating center (using the "Physician declaration" form) * Completion of the QLQ-C30 questionnaire (at inclusion, at each new treatment and then every 6 months). 4. Collection of retrospective and prospective data into the e-CRF by a local CRA using patients' medical files.
Study Type
OBSERVATIONAL
Enrollment
500
* Data collection from the medical file * Quality of life questionnaire (QLQC30) at inclusion, at each change of treatment and then every 6 months
University Hospital Graz
Graz, Austria
NOT_YET_RECRUITINGMedical University of Vienna
Vienna, Austria
NOT_YET_RECRUITINGMasaryk Memorial Cancer Institute (Masarykuv Onkologicky Ustav)
Brno, Czechia
NOT_YET_RECRUITINGAarhus University Hospital
Aarhus, Denmark
NOT_YET_RECRUITINGOverall Survival
To describe the survival rate of patients with solid cancers harboring a NTRK fusion or other rare actionable fusion in real-life practice, according to overall survival (OS)
Time frame: 2 years
Management of patient with actionable fusion
Treatment scheme : number of line and type of treatments
Time frame: up to 48 months
Time to relapse
Time frame: up to 48 months
Progression Free Survival (PFS)
Time frame: after 6, 12 and 24 months
Incidence of long-term responders
long term responders =: \> 24 months
Time frame: up to 48 months
Quality of life of patient
To evaluate patient-reported outcomes concerning individual QoL according to QLQ-C30 (EORTC Quality of Life questionnaires)
Time frame: After 6, 12, 18, 24, 30, 36, 42, 48 months
Time to relapse for fusion-targeting treatments
Time frame: up to 48 months
Overall survival for patient treated by fusion-targeting treatments
Time frame: 2 years
PFS for patient treated by fusion-targeting treatments
Progression free survival
Time frame: After 6, 12, 24 months of treatment by fusion targeting treatments
Incidence of long-term responders for patient treated by fusion-targeting treatments
\> 24 months
Time frame: up to 48 months
Quality of life of patient treated by fusion-targeting treatments
using QLQC30 (EORTC Quality of Life questionnaires)
Time frame: After 6, 12, 18, 24, 30, 36, 42, 48 months of fusion-targeting treatments
Safety : Nature of adverse reaction (for treatment targeting a fusion)
Using Common Terminology Criteria for Adverse Events (CTCAE) V5.0.
Time frame: up to 48 months
Safety : Frequency of adverse reaction (for treatment targeting a fusion)
Using Common Terminology Criteria for Adverse Events (CTCAE) V5.0.
Time frame: up to 48 months
Safety : Severity of adverse reaction (for treatment targeting a fusion)
Using Common Terminology Criteria for Adverse Events (CTCAE) V5.0.
Time frame: up to 48 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Chu Jean Minjoz
Besançon, France
NOT_YET_RECRUITINGInstitut Bergonie
Bordeaux, France
RECRUITINGCentre Georges Francois Leclerc
Dijon, France
NOT_YET_RECRUITINGCentre Oscar Lambret
Lille, France
NOT_YET_RECRUITINGChu Dupuytren
Limoges, France
NOT_YET_RECRUITINGCentre Léon Bérard
Lyon, France
RECRUITING...and 31 more locations